Cargando…
Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis
PURPOSE: This 2-year analysis assessed frequency of comorbidities and comorbidity screening in the Somatuline(®) (lanreotide, LAN) Depot for Acromegaly (SODA) registry. METHODS: Patient data collected included pituitary hormone deficiencies, sleep studies, echocardiograms, gallbladder sonographies,...
Autores principales: | Woodmansee, Whitney W., Gordon, Murray B., Molitch, Mark E., Ioachimescu, Adriana G., Carver, Don W., Mirakhur, Beloo, Cox, David, Salvatori, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997114/ https://www.ncbi.nlm.nih.gov/pubmed/29767287 http://dx.doi.org/10.1007/s12020-018-1615-3 |
Ejemplares similares
-
Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry
por: Salvatori, Roberto, et al.
Publicado: (2013) -
SAT622 Matched Physician- And Patient-reported Responses Of Acromegaly Symptom Control: Comparisons From The Macro Registry
por: Geer, Eliza Brevoort, et al.
Publicado: (2023) -
Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals
por: Ortendahl, Jesse D, et al.
Publicado: (2017) -
Hyposulphite of Soda
por: Marsh, J. W.
Publicado: (1891) -
Innovative treatment of hypercapnia with soda lime in COVID-19: a case report
por: Amoushahi, Ali, et al.
Publicado: (2023)